^
Association details:
| Biomarker: | AR mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | ODM-208 (CYP11A1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer
Published date:
12/26/2023
Excerpt:
Evidence of antitumor activity was observed in this heavily pretreated mCRPC population, especially in those with ARmut.
DOI:
10.1056/EVIDoa2300171
Trial ID:
Source:
Title:
Impact of activating androgen receptor (AR) mutations on AR sensitivity to alternative ligands and response to ODM-208, a selective, first-in-class CYP11A1 inhibitor, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC).
Published date:
05/26/2022
Excerpt:
Treatment with ODM-208 blocked all steroid hormone production and resulted in frequent ≥50% PSA reductions in this group of heavily pretreated mCRPC pts with various AR LBD mutations, some being long-lasting. cfDNA AR mutations are a promising predictive biomarker for ODM-208 efficacy.
DOI:
10.1200/JCO.2022.40.16_suppl.5057
Trial ID:
Source:
Title:
Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES)
Published date:
02/14/2022
Excerpt:
In evaluable patients with AR LBD mutation 10/15 (67%) achieved a PSA decline of =50%. Administration of ODM-208 to mCRPC men pretreated with abiraterone/enzalutamide and taxanes was highly effective in blocking the production of steroid hormones and showed promising antitumor activity, especially in men with AR mutation-positive cancers.
DOI:
10.1200/JCO.2022.40.6_suppl.018
Trial ID:
